Ignite Creation Date:
2024-05-05 @ 7:00 PM
Last Modification Date:
2024-10-26 @ 9:39 AM
Study NCT ID:
NCT00583323
Status:
COMPLETED
Last Update Posted:
2014-08-21
First Post:
2007-12-20
Brief Title:
Diphenoxylate Atropine to Decrease FDG Activity During F-18 FDG PET
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Diphenoxylate Atropine to Decrease Bowel Activity During F-18 FDG PET
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
2-18F-fluoro-2-deoxyD-glucose positron emission tomography FDG PET has proven to be a valuable clinical tool for the staging and surveillance of lymphoma1-6 Occasionally lymph nodes in the mesentery and retroperitoneum can be difficult to distinguish from normal bowel activity on PET scans despite three-plane and cine maximal image projection MIP imaging This uncertainty limits the clinical usefulness of PET in some cases of lymphoma7-8 In addition bowel activity can also hinder interpretation of PET scans in other types of solid tumors including melanoma and colorectal cancer6910 Our goal is to determine how well diphenoxylateatropine 5mg005mg Lomotil decreases bowel activity and how this decrease impacts clinical decision-making specifically for lymphoma staging and surveillance This is a prospective randomized double-blinded study involving 60 patients undergoing PET scans for newly diagnosed or recurrent untreated lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None